Key facts
- This page summarizes Henry Ji's Form 4 filing for Scilex Holding Co (SCLX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 31 Oct 2024, 12:44.
Henry Ji - 31 Oct 2024 Form 4 Insider Report for Scilex Holding Co (SCLX)
- Reporting relationship
- Executive Chairperson, Director
- Issuer ticker
- SCLX
- Reported as of
- 31 Oct 2024
- Net transaction value
- +$8,351
- SEC form
- 4
- Accepted by SEC
- 31 Oct 2024, 12:44:57 UTC
- Prior SEC filing
- 18 Oct 2024
- Next SEC filing
- 23 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jaisim Shah, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Henry Ji filed Form 4 for Scilex Holding Co (SCLX) on 31 Oct 2024.
Change
- Previous filing in this sequence was filed on 18 Oct 2024.
- Current net transaction value: +$8,351.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SCLX
transaction
Common Stock
Purchase
- Transaction value
- $8,351
- Shares
- +8,888
- Change %
- +2.9%
- Price
- $0.9396
- Shares after
- 320,161
- Date
- 31 Oct 2024
- Ownership
- Direct
- Footnotes
- F1
SCLX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 60,070
- Date
- 31 Oct 2024
- Ownership
- By BioVintage, Inc.
SCLX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,749
- Date
- 31 Oct 2024
- Ownership
- By BioVintage, Inc.
- Footnotes
- F2, F3
SCLX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 292,264
- Date
- 31 Oct 2024
- Ownership
- See Footnote
- Footnotes
- F4
SCLX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,640
- Date
- 31 Oct 2024
- Ownership
- By Spouse
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Open market purchase by the reporting person of 8,888 shares of common stock, par value $0.0001 per share (the "Common Stock").
Footnote F2
On December 30, 2022, the Board of Directors of Sorrento Therapeutics, Inc. ("Sorrento") declared a stock dividend (the "Dividend") to all holders of record of its common stock as of the close of business on January 9, 2023, of 0.1410127 of a share of Common Stock for each one share of common stock, par value $0.0001 per share, of Sorrento ("Sorrento Common Stock"). The Reporting Person wrote a put option in Sorrento Common Stock on August 26, 2022 (the "Put Option"), which was adjusted as a result of the Stock Dividend to relate to an aggregate of 19,500 shares of Sorrento Common Stock and 2,749 shares of Common Stock and to reflect a corresponding change to the exercise price of the Put Option to $0.80268 per share of Sorrento Common Stock and $8.6002 per share of Common Stock.
Footnote F3
The Put Option settled on March 17, 2023 and resulted in the Reporting Person becoming entitled to receive 2,749 shares of Common Stock at a price of $8.6002 per share of Common Stock, upon the expiration of the lock-up on such shares which is currently set to expire on January 31, 2025.
Footnote F4
Shares are held in family trusts of which the Reporting Person is a co-trustee with his spouse.